



1635
1 Fr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ATKINS1

In re Application of:) Conf. No.: 6813
David G. ATKINS) Art Unit: 1635
Filed: September 9, 2002) Examiner: James Shultz
Appln. No.: 09/889,075) Washington, D.C.
For: CATALYTIC MOLECULES) October 3, 2005

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

[X] C. after (A) and (B) above, but before final rejection or allowance, and Applicant has made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below):

[X] i. Counsel certifies that, upon information and belief, each item of information listed herein either was

[] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

[X] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this IDS.

[] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR §1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Anne M. Kornbau
Registration No. 25,884

AMK:srd

624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\B\Blaj\atkins1\pto\IDS 03 OCT 05.doc



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/889,075
Filing Date	September 9, 2002
First Named Inventor	David G. ATKINS
Group Art Unit	1635
Examiner Name	James Shultz

Attorney Docket Number

ATKINS1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AE	ADAMIS, A. P., et al., "Angiogenesis and Ophthalmic Disease", Angiogenesis, 1999, Vol. 3, pages 9-14	
	AF	BHUSHAN, M., "Recent Advances in Cutaneous Angiogenesis", British Journal of Dermatology, 2002, Vol. 147, pages 418-425	
	AG	DIGHTL, W., et al., "HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in human Endothelial and Vascular Smooth Muscle Cells", Arterioscler Thromb Vasc Biol., January 2003, pages 58-63	
	AH	FAHMY, R. G., et al., "Locked Nucleic Acid Modified DNA Enzymes Targeting Early Growth Response-1 Inhibit Human Vascular Smooth Muscle Cell Growth", Nucleic Acids Research, 2004, Vol. 32, No. 7, pages 2281-2285	
	AI	FAHMY, R. G., et al., "Transcription Factor Egr-1 Supports FGF-Dependent Angiogenesis During Neovascularization and Tumor Growth", Nature Medicine, August 2003, Vol. 9, No. 8, pages 1026-1032	
	AJ	FERRARA, N., et al., "The Biology of VEGF and Its Receptors" Nature Medicine, June 2003, Vol. 9, No. 6, pages 669-676	
	AK	HOFER, G., et al., "Transcription Factor Egr-1 Regulates Glomerular Mesangial Cell Proliferation", The Journal of Biological Chemistry, November 8, 1996, Vol. 271, No. 45, pages 28306-28310	
	AL	ITO, Y., et al., "Inhibition of Antiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4" Cancer Research, October 15, 2003, Vol. 63, pages 6651-6657	
	AM	JANSSEN, Y., et al., "Differential Induction of c-fos, c-jun, and apoptosis in Lung Epithelial Cells Exposed to ROS or RNS", 1997, pages L789-L796	
	AN	KRZYSTOLIK, M. G., et al., "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment", Arch. Ophthalmol., March 2002, Vol. 120, pages 338-346	
	AO	KUKITA, T., et al., "Regulation of Osteoclastogenesis by Antisense Oligodeoxynucleotide Specific to Zinc Finger Nuclear transcription Factors Egr-1 and WT1 in Rat Bone Marrow Culture System", Endocrinology, 1997, Vol. 138, No. 10, pages 4384-4389	
	AP	KURRECK, J., et al., "Comparative Study of DNA Enzymes and Ribozymes against the Same Full-length Messenger RNA of the Vanilloid Receptor Subtype I", The Journal of Biological Chemistry, March 1, 2002, Vol. 277, No. 9, pages 7099-7107	
	AQ	LEENDERS, W., et al., "Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flik-1 and Flt-1", Laboratory Investigation, April 2002, Vol. 82, No. 4, pages 473-481	
	AR	MALDVE, R. E., et al., "Tumor-Promoting Activity of 2,4-Dinitrofluorobenzene", Int. Journal Cancer, 1995, Vol. 60, pages 545-553	

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of


2

Complete if Known

Application Number	09/889,075
Filing Date	September 9, 2002
First Named Inventor	David G. ATKINS OCT 08 2005
Group Art Unit	1635
Examiner Name	James Shultz

Attorney Docket Number

ATKINS1



	AS	MITCHELL A., et al., "Inhibition of Human Breast Carcinoma Proliferation, Migration, Chemovasion and Solid Tumor Growth by DNAzymes Targeting The Zinc Finger Transcription Factor EGR-1", Nucleic Acids Research, 2004, Vol. 32, No. 10, pages 3065-3069	
	AT	MOMIYAMA, N., et al., "Suppression of c-jun by Antisense Oligonucleotide Inhibits Cell Adhesion but not Respiratory Burst During Phorbol Ester-Induced Differentiation of U937 Human Monoblastic Cells", Cell Growth & Differentiation, August 1996, Vol. 7, pages 1006-1012	
	AU	NAKAMURA, H., et al., "Introduction of DNA Enzyme for Egr-1 Into Tubulointerstitial Fibroblasts by Electroporation Reduced Interstitial α -smooth Muscle Actin Expression and Fibrosis in Unilateral Ureteral Obstruction (UUO) Rats" Gene Therapy, 2002, Vol. 9, pages 495-502	
	AV	NGUYEN, H. Q., et al., "The Zinc Finger Transcription Factor Egr-1 Is Essential for and Restricts Differentiation Along the Macrophage Lineage", Cell, January 29, 1993, Vol. 72, pages 197-209	
	AW	PAN, W., et al., "Identification of Efficient Cleavage Sites in Long-Target RNAs", Ribozymes and siRNA Protocols Second Edition; Methods in Molecular Biology, 2004, Vol 252, pages 125-144	
	AX	ROSS, R., "Atherosclerosis - An Inflammatory Disease" Mechanisms of Disease, January 14, 1999, Vol. 340, No. 2, pages 115-126	
	AY	SANTORO, S., et al., "A General Purpose RNA-Cleaving DNA Enzyme", Proc. Natl. Acad. Sci. USA, April 1997, Vol. 94, pages 4262-4266	
	AZ	SCHERER, L. J., et al., "Approaches for the Sequence-Specific Knockdown of mRNA", Nature Biotechnology, December 2003, Vol. 21, No. 12, pages 1457-1465	
	BA	SELLS, S. F., et al., "The Zinc Finger Transcription Factor EGR-1 Impedes Interleukin-1-Inducible Tumor Growth Arrest", Molecular Cellular Biology, February 1995, Vol. 15, No. 2, pages 682-692	
	BB	SUGGS, S. V., et al., "cDNA Sequence of the Human Cellular Early Growth Response Gene Egr-1", Nucleic Acids Research, April 13, 1990, Vol. 18, No. 14, EMBL accession no. X52541, page 4283	
	BC	VAN NIEUW AMERONGEN, G. P., et al., "Targets of Pharmacological Intervention of Endothelial Hyperpermeability and Barrier Function", Vascular Pharmacology, 2003, Vol. 39, pages 257-272	
	BD	WANG, N., et al., "Adenovirus-Mediated Overexpression of Dominant-Negative Mutant of C-Jun Prevents Intercellular Adhesion Molecule-1 Induction by LDL", Arterioscler Thromb Vasc Biol., September 2001, pages 1414-1420	
	BE	YAMADA, M., "Molecular Mechanism and Role of Endothelial Monocyte Chemoattractant Protein-1 Induction by Vascular Endothelial Growth Factor", Arterioscler Thromb Vasc Biol., November 2003, pages 1996-2001	
	BF	YOKOTA, T., et al., "siRNA-Based Inhibition Specific for Mutant SOD1 with Single Nucleotide Alteration in Familial ALS, Compared with Ribozyme and DNA Enzyme", Biochemical and Biophysical Research Communications, 2004, Vol. 314, pages 283-291	
	BG	ZHANG, G., et al., "Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents", Journal of the National Cancer Institute, May 5, 2004, Vol. 96, No. 9, pages 683-696	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.